Background illustration for clinical trials search

Paid Clinical Trials Durham

Discover 1,668 paid clinical trials in Durham, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Durham NC, Chapel Hill NC, Raleigh NC, Richmond VA,
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase 3, Recruiting

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

for
Lipoprotein(a)
Location: Durham NC, Kingsport TN, Manassas VA, Rockville MD,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07614984

Phase 2, Recruiting

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

for
Coronavirus Infection, Severe Acute Respiratory Infection,
Location: Durham NC, Washington DC, Bethesda MD, Baltimore MD,
Sponsor: Biomed Industries, Inc.

Sex: All

Age: 18 - 70+

Code: NCT04452565

Phase 2, Phase 3, Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

for
Multiple System Atrophy
Location: Durham NC, Pittsburgh PA, New York NY, Tampa FL,
Sponsor: Teva Branded Pharmaceutical Products R&D LLC

Sex: All

Age: 30+

Code: NCT07197866

Phase 2, Recruiting

Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout

for
Hyperuricemia, Gout
Location: Durham NC
Sponsor: Pharmos

Sex: All

Age: 18 - 65

Code: NCT01519687

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

for
Sjögren's Syndrome
Location: Durham NC, Charlotte NC, Salisbury NC, Beckley WV,
Sponsor: Amgen

Sex: All

Age: 18+

Code: NCT06747949

Phase 3, Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

for
Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Location: Durham NC, Baltimore MD, Philadelphia PA, Columbus OH,
Sponsor: Alnylam Pharmaceuticals

Sex: All

Age: 0+

Code: NCT04561518

Recruiting

Infancy to Toddlerhood: Early Nutrition & Tolerance (INTENT)

for
Diet Diversity, Infant Nutrition
Location: Durham NC
Sponsor: Before Brands, Inc

Sex: All

Age: 0

Code: NCT04803981

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

for
Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed,
Location: Durham NC, Richmond VA, Greenville SC,
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT06465810

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for
Non-Small Cell Lung Cancer
Location: Durham NC, Chapel Hill NC, Pinehurst NC, Blacksburg VA,
Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT06767514

Phase 3, Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

for
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors,
Location: Durham NC, Washington D.C. DC, Cincinnati OH,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 1 - 70+

Code: NCT05868629

Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

for
Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis,
Location: Durham NC, Chapel Hill NC, Columbus OH, Chattanooga TN,
Sponsor: argenx

Sex: All

Age: 18+

Code: NCT07294170

Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

for
AChR-Ab Seropositive Generalized Myasthenia Gravis,
Location: Durham NC, Chapel Hill NC, Columbus OH, Chattanooga TN,
Sponsor: argenx

Sex: All

Age: 18+

Code: NCT07284420

Phase 2, Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Durham NC, Charlotte NC, Midlothian VA, Norfolk VA,
Sponsor: Olema Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07085767

Phase 3, Recruiting

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

for
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma,
Location: Durham NC, Fairfax VA, Cleveland OH, New York NY,
Sponsor: Plexium, Inc.

Sex: All

Age: 18+

Code: NCT07284186

Phase 1, Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

for
Metastatic Clear Cell Renal Cell Carcinoma,
Location: Durham NC, Chapel Hill NC, Charlottesville VA,
Sponsor: Arcus Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07011719

Phase 3, Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

for
Cardiovascular, Metabolic Disease, Dyslipidemias,
Location: Durham NC, High Point NC, Jacksonville FL,
Sponsor: CRISPR Therapeutics AG

Sex: All

Age: 18 - 70+

Code: NCT07491172

Phase 1, Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

for
Systemic Lupus Erythematosus
Location: Durham NC, Washington D.C. DC, Philadelphia PA,
Sponsor: AstraZeneca

Sex: All

Age: 5 - 17

Code: NCT05835310

Phase 3, Recruiting

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

for
Glycogen Storage Disease Type II Infantile Onset
Location: Durham NC, Pittsburgh PA, Atlanta GA, Cincinnati OH,
Sponsor: Amicus Therapeutics

Sex: All

Age: 0 - 17

Code: NCT04808505

Phase 3, Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for
End Stage Kidney Disease
Location: Durham NC, Raleigh NC, Greenville NC, Charlotte NC,
Sponsor: CSL Behring

Sex: All

Age: 18+

Code: NCT05485961

Phase 2, Phase 3, Recruiting